DRIVIN G ROWTH - Dr. Reddy's

18
emerging businesses
BEYOND THE FIRST STEPS
CRITICAL CARE DIVISION
I
N THE CRITICAL CARE
DIVISION(CCD), our vision is
to create a strong base in specialty
segments for a sustainable long-term
competitive advantage. To meet this
objective, opportunities and issues have
been identified and strategies formulated to
exploit the opportunities.
Currently, the CCD deals with high value
low volume oncology products. The
Oncology market is a fast growing segment,
with more and more players vying for a
share of this pie. The last few years have
L IQUID C HROMATOGRAPH – Analytical facility at emerging businesses
DR. REDDY’S LABORATORIES LTD. | EMERGING BUSINESSES | ANNUAL REPORT 2001-2002
seen the entry of some players in this
market. The total Oncology market in India
is estimated to be approximately Rs. 250
crores growing at a rate of 20%. This
segment is growing at a rate faster than that
of the industry.
There are 22 players in the Indian
Oncology market. The CCD of Dr. Reddy’s
has taken a big leap from 4th rank in the
year1999-2000 to 2nd rank in the year
2000-2001 and as on date enjoys the
leadership status. Most of the products
launched by CCD have achieved leadership
status in their respective groups. Such a
commendable performance has been
possible only because CCD has been able to
successfully differentiate itself from the rest.
CCD recorded a sale of Rs. 25.6 crores in
financial year 2001–02 with a revenue
growth rate of 40% over the last financial
year. Financial year 2001-02 also witnessed
Dr. Reddy’s foray into the field of
biotechnology with the launch of Grastim a
brand of G-CSF. On annualised basis
Grastim is the market leader not only in
terms of units but also in terms of value. In
the financial year 2002-03, CCD intends to
maintain and consolidate the pole position
in the Oncology segment and continue to
widen the gap vis-a-vis competition. The
beginning of FY 2002-03 marked the entry